Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 325 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 325 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $399.99, for a total value of $129,996.75. Following the completion of the transaction, the chief financial officer owned 46,249 shares of the company’s stock, valued at $18,499,137.51. The trade was a 0.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, November 3rd, Michael Brophy sold 470 shares of Natera stock. The stock was sold at an average price of $391.49, for a total value of $184,000.30.
• On Wednesday, October 28th, Michael Brophy sold 1,178 shares of Natera stock. The stock was sold at an average price of $426.46, for a total transaction of $502,369.88.
• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.

Natera Stock Performance

NASDAQ:NTRA opened at $363.76 on Friday. The company has a 50-day moving average of $380.81 and a 200-day moving average of $269.30. The company has a market capitalization of $52.43 billion, a price-to-earnings ratio of -267.47 and a beta of 1.55. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The business had revenue of $793.98 million for the quarter, compared to analyst estimates of $707.54 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 34.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.64) earnings per share. Sell-side analysts forecast that Natera, Inc. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Natera during the second quarter worth $2,962,770,000. Arrowstreet Capital Limited Partnership lifted its position in Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after acquiring an additional 11,793 shares in the last quarter. Maverick Capital Ltd. boosted its stake in Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after purchasing an additional 80,440 shares during the period. Finally, Bank of America Corp DE bought a new position in Natera during the 2nd quarter worth about $199,960,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group upped their price objective on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Barclays increased their target price on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. BTIG Research raised their target price on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research report on Tuesday, October 27th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Finally, Morgan Stanley upped their price target on Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $394.31.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794.0 million, exceeding analyst expectations of about $707.5 million. The result points to continued business growth. Natera third-quarter 2026 results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Neutral Sentiment: Gross margin was 64.7%, nearly unchanged from 64.9% a year earlier, indicating that strong sales growth came with broadly stable margin performance. Natera third-quarter 2026 results
• Neutral Sentiment: Several executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales may attract attention, but their stated purpose and scheduled nature make them less informative about management’s outlook. Natera insider transaction
• Negative Sentiment: Natera reported a quarterly loss of $0.42 per share, wider than analysts’ expected loss of $0.28. The earnings miss likely outweighed the revenue beat and added pressure on the stock. Natera third-quarter 2026 results

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.